Form 4: Syros Pharmaceuticals CEO Sells 134,797 Shares at Weighted Average Price of $0.1998

Syros Pharmaceuticals' CEO, Chee Conley, sold 134,797 shares of common stock at a weighted average price of $0.1998 on November 18, 2024.

Summary

• Syros Pharmaceuticals' CEO, Chee Conley, executed a sale of 134,797 common stock shares on November 18, 2024.
• The shares were sold at a weighted average price of $0.1998.
• The sale was conducted in multiple transactions with prices ranging from $0.1836 to $0.2071 per share.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale by an insider. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders trade their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are a common occurrence for publicly traded companies, and this transaction is consistent with standard practices.
• The sale of shares by a CEO is not unusual, but the market may react to the news depending on the size of the transaction and the company's current performance.

Stakeholder Impact

• The sale of shares by the CEO could potentially influence investor sentiment, although the impact is likely to be minimal given the size of the transaction relative to the company's market capitalization.

Key Dates

Keywords

Syros Pharmaceuticals, SYRS, insider trading, stock sale, Chee Conley, CEO, common stock